Rituximab Therapy in Pulmonary Alveolar Proteinosis: A Case Report
2024

Rituximab Therapy in Pulmonary Alveolar Proteinosis: A Case Report

Sample size: 1 publication Evidence: low

Author Information

Author(s): Muacevic Alexander, Adler John R, Fikri Oussama, Hindi Meryem, Amro Lamyae

Primary Institution: Centre Hospitalier Universitaire (CHU) Mohammed VI, Arrazi Hospital, Faculté de Médecine et de Pharmacie de Marrakech, Laboratoire de Recherche Morpho Sciences, Université Cadi Ayyad

Hypothesis

Can rituximab effectively treat autoimmune pulmonary alveolar proteinosis?

Conclusion

Rituximab treatment led to significant improvement in respiratory function and regression of radiological lesions in a patient with autoimmune pulmonary alveolar proteinosis.

Supporting Evidence

  • Rituximab was administered successfully, leading to marked improvement in respiratory function.
  • The patient experienced significant regression of radiological lesions within two months.
  • Rituximab treatment was well tolerated by the patient.

Takeaway

A woman with a rare lung disease got better after taking a medicine called rituximab, which helped her breathe easier.

Methodology

The patient received two intravenous doses of rituximab, 1,000 mg each, on day 1 and day 15, after a thorough pre-treatment evaluation.

Limitations

The study is based on a single case report, limiting generalizability.

Participant Demographics

49-year-old female homemaker with a history of passive smoking and exposure to wood smoke and pigeon droppings.

Digital Object Identifier (DOI)

10.7759/cureus.73836

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication